Mart-1
Melanoma
National Cancer Institute (NCI)protein_peptidePhase 2Dormant
CCC
51/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 65/ 100
Competitive context
329 Active assets in the Melanoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
DACARBAZINE Suzhou BlueHorse Therapeutics Co., Ltd. | Phase 3 | BB |
Cyclophosphamide Primmune Therapeutics, Inc. | Phase 4 | BB |
Nivolumab Bristol-Myers Squibb | Phase 4 | BB |
Epirubicin Primmune Therapeutics, Inc. | Phase 4 | BB |
Pembrolizumab Biocon Biologics UK PLC | Phase 4 | BB |
View all 50 →
Same molecule, other indications
Mart-1 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →